Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

@article{Suda2010BiologicalAC,
  title={Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation},
  author={K. Suda and K. Tomizawa and T. Mitsudomi},
  journal={Cancer and Metastasis Reviews},
  year={2010},
  volume={29},
  pages={49-60}
}
KRAS and epidermal growth factor receptor (EGFR) are the two most frequently mutated proto-oncogenes in adenocarcinoma of the lung. The occurrence of these two oncogenic mutations is mutually exclusive, and they exhibit many contrasting characteristics such as clinical background, pathological features of patients harboring each mutation, and prognostic or predictive implications. Lung cancers harboring the EGFR mutations are remarkably sensitive to EGFR tyrosine kinase inhibitors such as… Expand
View on Springer
ncbi.nlm.nih.gov
188 Citations
Highly Influential Citations
8
Background Citations
69
Methods Citations
3
Results Citations
5

188 Citations

Citation Type

Citation Type

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
  • 4
  • PDF
EGFR and KRAS mutation coexistence in lung adenocarcinomas
  • 1
Successes and limitations of targeted cancer therapy in lung cancer.
  • 25
Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
  • 10
  • PDF
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
  • 116
Drug Combinatorial Therapies for Treatment of KRAS Mutated Lung Cancers.
  • 4
Bladder and Gastric Metastases from Lung Adenocarcinoma Harboring Codon 13 KRAS Mutation: a Case Report with Unusual Clinical Outcome
  • 1
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
  • 47
Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients
  • 22
  • PDF
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.
  • 46
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 106 REFERENCES
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
  • 2,038
  • PDF
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
  • 607
  • PDF
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  • 8,652
  • PDF
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
  • 1,147
  • PDF
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer
  • 106
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
  • 537
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
  • R. Leidner, P. Fu, +10 authors B. Halmos
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
  • 84
  • Highly Influential
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
  • 10,169
  • PDF
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
  • 904
Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma
  • 205
...
1
2
3
4
5
...